From Research at med.fsu.edu Wed Nov 4 14:01:08 2020 From: Research at med.fsu.edu (Med Research) Date: Wed, 4 Nov 2020 19:01:08 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A177313B@FSUCOM128.med.ad.fsu.edu> REMINDER: Toffler Scholar Program applications are due MONDAY, NOVEMBER 9, 2020. Toffler Scholar Program Open to FSU researchers. The Toffler Scholar Program was created by the Trustees of the Karen Toffler Charitable Trust, a 501 C3 nonprofit foundation focused on early-stage research that advances the medical field in profound, high-impact ways. Tapping into the deep legacy of their founders, best-selling authors and futurists, Alvin and Heidi Toffler, the trust exists to be a catalyst for future ? focused breakthroughs. The Toffler Scholar Program focuses on helping university medical researchers gain access to support, and a network for often underfunded innovations. It is a nimble source of financial support for medical researchers working on early-stage, future-focused brain science. Together with the FSU College of Medicine, the program helps foster new ways of thinking and problem solving to find solutions to humanity?s most difficult problems. Toffler Scholar grants are one-year grants that currently range from $20,000 - $30,000 per award. Due November 9, 2020. Med-RA draft review is not required. Desmoid Tumor Research The Desmoid Tumor Research Foundation welcomes applications for its research grant program. Through the program, grants of up to $65,000 will be awarded for research that advances current scientific knowledge of desmoid tumors using science and creative clinical applications, as well as novel approaches that addresses potential leads based on prior research. Proposals with additional sources of funding support are particularly desirable, and researchers must be willing to collaborate with other scientists and institutions with similar interests. Grantees must agree to participate as reviewers in DTRF?s future grant review cycle and present the results of their research at the annual September International DTRF Desmoid Tumor Research Workshop. Due December 1, 2020. Med-RA deadline to receive draft documents: November 16 (due to Thanksgiving break). American Lung Association: Innovation Awards The American Lung Association works to fight lung disease by advancing treatment and unlocking the secrets of the body?s immune system, including breakthroughs in the fight against tuberculosis, identifying the genes that cause the development of lung cancer and cystic fibrosis, and developing innovative ways to treat respiratory distress syndrome. To help advance this mission, ALA is inviting applications for its Innovation Award program. Through the program, grants of up to $75,000 a year for up to two years will be awarded in support of highly promising investigators with stellar track records of accomplishment and the potential to advance the field of lung disease science. Note: Applicants must have held a K or R type award within three years prior to applying for this award. Due December 10, 2020. Med-RA deadline to receive draft documents: November 30. Misophonia Research Proposals must address one or more of the following three broad areas in human, animal, or relevant research models: 1) research focused on characterizing misophonia, including exploring its underlying mechanisms, expression, natural history, and/or development; 2) development of diagnostic tools to facilitate rapid, physiologically-relevant assessment; 3) clinical and/or model studies of specific interventions, including studies investigating comparative effectiveness, novel treatments, and controlled trials of promising treatments The program supports two-year projects led by either faculty members or postdocs with annual budgets of up to $200,000. Letter of intent due December 11, 2020. Med-RA deadline to receive draft documents: November 30. Treatments for Lewy Body Dementias?Exploratory Clinical Trial (U01 Clinical Trial Required) This Funding Opportunity Announcement invites applications from investigators seeking to conduct exploratory clinical trials designed to test new treatments for patients with Lewy Body Dementia (LBD). Applicants may propose to conduct either Phase I or Phase II clinical trials depending on the developmental stage of the potential therapeutic, but all trials must include patients with LBD. Proposed therapies may include novel medications or devices, or existing treatments that are potentially beneficial but not currently approved for use in patients with LBD. Treatments intended to prevent or delay disease progression in LBD patients, as well as therapies to alleviate existing motor or non-motor clinical symptoms, are of interest. Due March 2, 2020. Med-RA deadline to receive draft documents: February 17. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Fri Nov 20 14:08:33 2020 From: Research at med.fsu.edu (Med Research) Date: Fri, 20 Nov 2020 19:08:33 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A1777D20@FSUCOM128.med.ad.fsu.edu> Research Supplements to Promote Diversity in Health-Related Research (Admin Supp ? Clinical Trial Not Allowed) The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Due dates vary by awarding IC. Expires May 8, 2023. Med-RA deadline to receive draft documents: Ten business days before sponsor deadline. American Lung Association: Public Policy Research Award The American Lung Association works to save lives by improving lung health and preventing lung disease, with a focus on four strategic imperatives: to defeat lung cancer, reduce the burden of lung disease on individuals and their families; eliminate tobacco use and tobacco-related diseases, and improve the air we breathe. To that end, the organization is inviting applications for its Public Policy Research Award program. Through the program, grants of up to $50,000 per year for up to two years will be awarded in support of research on and the evaluation of existing public policy and programs, as well as pilot and demonstration projects that inject innovative ideas and provide evidence for the development of new public policies impacting lung health. The call for proposals is open to researchers in public policy, economics, political science, sociology, law, and related disciplines; applicants should be on -track to pursue a career in public policy research. Investigational areas of interest are broad and include but are not limited to: tobacco control, air quality, health policy, disparities, modeling, and informatics. Due December 10, 2020. Med-RA deadline to receive draft documents: November 30. American College of Obstetrics and Gynecology: Warren H. Pearse Women?s Health Policy Research Award This research award will provide $10,000 to support research which explores an aspect of health care policy that assists, defines, or restricts the ability of a physician to deliver health care to women in the general population, or in a specific area. Due December 15, 2020. Med-RA deadline to receive draft documents: December 2. Robert Wood Johnson Foundation: Health Data for Action (HD4A) HD4A aims to reduce the barriers often faced in accessing rich data by serving as a conduit between data owners and interested researchers. Through this HD4A call for proposals (CFP), RWJF will make valuable data from unique data owners available to researchers. The purpose of the 2020 HD4A CFP is primarily to award data access at no cost from one of eight anticipated data providers to successful applicants. Most selected projects will not receive a financial award for personnel or other project-related costs. However, limited funding up to $100,000 per project is available for a small number of projects from principal investigators who have not previously received external research funding. The HD4A program will support innovative research that uses the available data to answer important research questions. Applicants under this CFP will write a proposal for a research study using data from one of the following anticipated data providers including: athenahealth; CareJourney VRDC T-MSIS Research Collaborative; the Center for Improving Value in Health Care (CIVHC); Geisinger; the Health Care Cost Institute (HCCI); HealthShare Exchange (HSX); OCHIN ADVANCE Collaborative; and TransUnion. Eligible research projects can focus on a variety of topics, including health care utilization and spending; benefit design; quality of care; prescribing patterns and medication adherence; chronic disease; maternal and child care; complex conditions; employer-sponsored insurance; public and private insurance; consolidation; integration, and market competition; social determinants of health and disparities; COVID-19 patient characteristics and outcomes; financial distress; mental health; housing instability; opioid use and treatment; and geographic variation in health. Brief proposals due December 17, 2020. Med-RA deadline to receive draft documents: December 10. Elsa U. Pardee Foundation: Cancer Research Grants The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified. By design, there are no limits set on the grant amount that can be requested. It must be reasonably and clearly supported by the scope of the project outlined in the application. Due December 31, 2020; April 30, 2021; and August 31, 2021. Med-RA deadline to receive draft documents for December 2020 due date: December 7 (due to Winter Break). Strengthening HIV Prevention Efforts for Women in the Southern U.S. (R34 / R01 Clinical Trial Optional) R34 R01 These Funding Opportunity Announcements invites applications for research that will increase the use of HIV prevention strategies among women in the southern U.S. by elucidating barriers and facilitators to their utilization and developing and testing interventions to enhance uptake, adherence, and persistence. Research should focus on strategies within the following three potentially overlapping areas: implementation science, health communication research, and services research. Due January 11, 2021. Med-RA deadline to receive draft documents: December 15 (due to Winter Break). Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional) This initiative will support research projects that test the effectiveness of multi-level interventions to prevent HIV in high-risk health disparity populations or subgroups in one or more geographic areas with a high rate of new HIV infections. Due January 15, 2021. Med-RA deadline to receive draft documents: January 4. NIAAA Resource-Related Research Projects (R24 Clinical Trial Not Allowed) The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research applications should not be submitted in response to this program announcement but to another mechanism that encourages this type of research. The resource should be available to any qualified investigator, and should be highly quality controlled, and not duplicate resources available commercially or through other sources. Resources should be designed to provide services to the broad alcohol research community and should not be limited by any specific regional focus. Standard dates apply. Expires September 26, 2023. Med-RA deadline to receive draft documents for January 25 standard date: January 11. Stephen I. Katz Early Stage Investigator Research Project Grants R01 Basic Experimental Studies with Humans Required R01 Clinical Trial Not Allowed Stephen I. Katz Early Stage Investigator Research Project Grants support innovative projects that represent a change in research direction for an early stage investigator and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement must not include preliminary data. Applications must include a separate attachment describing the change in research direction. Due January 26, 2021; May 26, 2021; September 28, 2021; January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023. Med-RA deadline to receive draft documents for January 2021 due date: January 12. National Cancer Institute?s Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute?s (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the NCI DCTD website and/or the OHAM website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Standard dates apply. Expires January 8, 2024. Med-RA deadline to receive draft documents for February 5 standard date: January 25. Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Standard dates apply. Expires January 8, 2024. Med-RA deadline to receive draft documents for February 5 standard date: January 25. Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01 Clinical trial not allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations. Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for February 5 standard date: January 25. Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01 Clinical Trial Optional) The purpose of this initiative is to support research to design and implement effective interventions to enhance health advantages and reduce the health disparities among US immigrant populations. Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for February 5 standard date: January 25. New York Stem Cell Foundation: Stem Cell Investigator Awards and Neuroscience Investigator Awards RFP: Robertson Stem Cell Investigator Awards NYSCF is soliciting applications from early career investigators for Innovator Awards to be used for exploring the basic biology and translational potential of stem cells. The goal of this initiative is to foster bold and innovative scientists with the potential to transform the field of stem cell research, and advance understanding and use of stem cells in the development of treatments for human disease. Grants of $1.5 million over five years will be awarded . Due February 17, 2021. Med-RA deadline to receive draft documents: February 4. RFP: Robertson Neuroscience Investigator Awards NYSCF is soliciting applications from early career investigators for awards in neuroscience. New this year, NYSCF especially encourages applications from neuroscientists whose research is focused on human systems. This might include research using patient-derived model systems and approaches using samples or data (genomic, epidemiological, imaging, real-world data, etc.) collected from individuals or human populations. Through the program, grants of $1.5 million over five years will be awarded to early-career investigators in support of bold, innovative research with the potential to transform the field of neuroscience. Due February 17, 2021. Med-RA deadline to receive draft documents: February 4. Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R34 / R01 Clinical Trial Optional) R34 R01 NIMH seeks applications for pilot and research projects to evaluate the effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Given the focus on practice-ready accessible resources and products that could be readily integrated into practice, NIMH encourages the use of technology and other design features that make the tools scalable and robust against implementation drift, and a deployment-focused approach that takes into account the perspectives of key stakeholders (e.g., service users, providers, administrators) and system-level factors, such as workforce capacity that influence potential integration of tools into clinical workflows. Due February 18, 2021; October 15, 2021; and June 15, 2022. Med-RA deadline to receive draft documents for February 2021 due date: February 8. Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed) Several valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this funding opportunity announcement (FOA) is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund (https://commonfund.nih.gov/) data sets, including generating hypotheses and catalyzing discoveries. Award recipients are asked to provide feedback on the utility of the Common Fund data resources. Due February 19, 2021. Med-RA deadline to receive draft documents: February 8. Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required) This Funding Opportunity Announcement (FOA) is designed to facilitate clinical trials that can be completed within a limited timeframe and budget. A broad range of types of exploratory studies may be submitted to this FOA. The trials must address research questions related to the mission and goals of the NIAMS and may evaluate interventions with drugs, biologics, devices, or surgical, dietary, behavioral or rehabilitation therapies. March 4, 2021; July 2, 2021; November 2, 2021; March 4, 2022; July 1, 2022; November 4, 2022; March 3, 2023; July 2, 2023; and November 3, 2023. Med-RA deadline to receive draft documents for March 2021 due date: February 22. Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. A future clinical study may include a clinical trial or an observational study. Research data from observational studies supported by this FOA can enhance clinical study design by providing essential information about disease symptoms, stages, and timing of disease progression; comorbid conditions; availability of potential research participants; and outcomes that are important to patients. They also can facilitate efforts to develop and/or validate objective biomarkers or subjective outcome measures for use in a future clinical study. Applicants to this FOA are encouraged to propose studies that address significant obstacles or questions in the design of a clinical project, such as determining the appropriate primary or secondary outcome measures or identifying the stages of disease during which patients are most likely to respond to an intervention. Only observational studies will be supported through this FOA. Due March 4, 2021; July 2, 2021; November 2, 2021; March 4, 2022; July 1, 2022; November 4, 2022; March 3, 2023; July 2, 2023; and November 3, 2023. Med-RA deadline to receive draft documents for March 2021 due date: February 22. NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) This Funding Opportunity Announcement (FOA) solicits cooperative agreement (U01) applications for implementation of investigator-initiated interventional clinical trials (all phases). Applications for clinical trials submitted to the NIAMS are normally expected to go through a two-part process, which begins with an R34 planning phase (Part 1) followed by an application for the U01 (Part 2). Investigators who have completed all necessary pre-trial planning and preparation through other means may apply for a NIAMS U01 without an awarded R34. The NIAMS expects trials to be hypothesis-driven and have the potential for high impact within the research mission of the NIAMS. Due March 4, 2021; July 2, 2021; November 2, 2021; March 4, 2022; July 1, 2022; November 4, 2022; March 3, 2023; July 2, 2023; and November 3, 2023. Med-RA deadline to receive draft documents for March 2021 due date: February 22. Detection of HIV for Self-Testing (R61/R33) The purpose of this Funding Opportunity Announcement is to support collaborative, interdisciplinary early-stage research to inform the development of innovative rapid, sensitive, simple, and cost-effective diagnostic technologies that will enable HIV self-testing during the earliest phases of acute infection or during viral rebound. Due March 17, 2021; March 17, 2022; and March 17, 2023. Med-RA deadline to receive draft documents for March 2021 due date: March 4. Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34 / R01 Clinical Trial Optional) R34 R01 The purpose of these FOAs is to support the development, adaptation, and pilot testing of implementation strategies to achieve system-level adoption of evidence-based interventions, guidelines, or practices to improve the delivery, quality, and sustainability of prevention or treatment services for substance use disorders. Due July 19, 2021; November 15, 2021; July 19, 2022; November 15, 2022; July 19, 2023; and November 15, 2023. Med-RA deadline to receive draft documents for July 2021 due date: July 6. Forecasts Health Resources and Services Administration Evidence-based Telehealth Network Program The two-fold purpose of Evidence Based Telehealth Network Program is to (1) demonstrate how health care systems can increase access to health care services utilizing Direct-to-Patient Telehealth technologies and (2) to conduct evaluations of those efforts to establish an evidence base for assessing the effectiveness of Direct-To-Patient Telehealth care for patients, providers, and payers. Estimated post date: January 20, 2021 Estimated due date: March 22, 2021 Health Resources and Services Administration Rural Maternity and Obstetrics Management Strategies The purpose of the Rural Maternity and Obstetrics Management Systems (RMOMS) program is to improve access to and continuity of maternal and obstetrics care in rural communities. The goals of the RMOMS program are to: (i) improve maternal and neonatal outcomes within a rural region; (ii) develop a sustainable network approach to increase the delivery and access of preconception, pregnancy, labor and delivery, and postpartum services; (iii) develop a safe delivery environment with the support and access to specialty care for perinatal women and infants; and (iv) develop sustainable financing models for the provision of maternal and obstetrics care in rural hospitals and communities. Applicants are encouraged to propose innovative ways to achieve these goals through an established or formal regional network structure. Estimated post date: January 29, 2021 Estimated due date: March 30, 2021 To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: